Evidence map›Paper›PMID 41331235›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Population-Based Multi-Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease.

Tianxing Wu, Jialiang Luo, Haoyuan Qiu, Weijie Shao, Yueyang Lu, Meixuan Luo, Zhaofeng Lin, Yan Zhang, Libo Zhang, Hong Wang and 4 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tianxing WuClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.ORCID https://orcid.org/0009-0002-6542-4704
Jialiang LuoInstitute of Molecular Immunology, Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Haoyuan QiuClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.
Weijie ShaoDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Yueyang LuInstitute of Molecular Immunology, Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Meixuan LuoClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.
Zhaofeng LinClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.
Yan ZhangClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.
Libo ZhangThe First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Hong WangInstitute of Molecular Immunology, Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Jia ZhouDepartment of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510515, China.
Guangfeng RuanClinical Research Centre, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510180, China.
Peihua CaoClinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510260, China.
Daming ZuoInstitute of Molecular Immunology, Guangdong Provincial Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China.ORCID https://orcid.org/0000-0003-2003-9474

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515011518Guangdong S&T programme 2024A0505040013National Natural Science Foundation of China 82271782National Natural Science Foundation of China 82303982National Natural Science Foundation of China 82472478Science and Technology Program of Guangzhou 202201011245Shenzhen Medical Research Fund A2401047Shenzhen Medical Research Fund A2501018
6 · The paper itself

Abstract

Psoriatic disease (PsD) is a chronic inflammatory disease, with significant challenges in early risk stratification and drug development. Integration of proteomic and genomic data provides an unprecedented opportunity to identify predictive biomarkers and therapeutic targets for PsD. Here, through systemic genetic analyses, expression validation, and prospective cohort study, CDSN and PRSS8 were identified as candidate biomarkers and potential therapeutic targets for PsD. Individuals with higher levels of CDSN and PRSS8 were nearly three times more likely to develop PsD compared to the general population. It develops prediction models in adults without PsD at baseline from the UK Biobank. Combining CDSN and PRSS8 with demographics produced desirable predictions for PsD (area under the curve (AUC) = 0.80) and exhibited high specificity. Moreover, PRSS8 and CDSN were both predominantly localized in keratinocytes, and in vivo gene silencing of these proteins significantly reduced PsD-like skin lesions and systemic inflammatory markers. The findings strongly suggested that CDSN and PRSS8 are promising biomarkers for PsD onset and progression, providing a 12-year risk assessment window and potential as novel therapeutic targets. These results had important implications for screening high-risk populations and facilitating early intervention for PsD.

Indexed as

BiomarkersPsoriasisAdultCohort StudiesFemaleHumansMaleMiddle AgedMultiomicsProspective StudiesProteomicsBiomarkersbiomarkerpredictive modelpsoriatic diseasesi‐RNAtherapy

Identifiers

PMID41331235
PMCPMC12884755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.